Highlights Mustang Bio, Inc.

Equities

MBIO

US62818Q2030

Delayed Nasdaq Other stock markets 03:58:33 2024-06-10 pm EDT			5-day change	1st Jan Change
0.1358 ^USD	-8.55%		-24.23%	-89.95%

May. 15	Mustang Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 02	Mustang Bio, Inc. announced that it has received $3.3 million in funding	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mustang Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Mustang Bio Prices Public Offering of 16.9 Million Shares, Accompanying Warrants	Apr. 30	MT
North American Morning Briefing : Stock Futures Rise Despite Middle East Tensions	Apr. 15	DJ
Mustang Bio, Inc Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases	Mar. 28	CI
Mustang Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
Mustang Bio, Inc. Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101IL13Ra2-targeted CAR T-Cells in High-Grade Glioma	Mar. 07	CI
Mustang Bio, Inc. Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology Annual Meeting	Dec. 11	CI
Mustang Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Mustang Bio, Inc. Announces Interim Phase 1/2 Data from Mustang's Multicenter Clinical Trial of MB-106	Nov. 02	CI
Mustang Bio, Inc. Announces FDA Acceptance of IND Application for MB-109, A Novel Combination of MB-101 (IL13RA2-Targeted Car-T Cell Therapy) and MB-108 (HSV-1 Oncolytic Virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma	23-10-26	CI
Mustang Bio, Inc. Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy	23-08-16	CI
Mustang Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
UBriGene Biosciences Inc. completed the acquisition of Worcester manufacturing facility of Mustang Bio, Inc.	23-07-27	CI
Mustang Bio, Inc. Terminates Exclusive License Agreement with Regents of the University of California	23-07-11	CI
Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy	23-06-15	CI
Mustang Bio to Sell Massachusetts Manufacturing Facility to uBriGene for $11 Million	23-05-18	MT
UBriGene Biosciences Inc. entered into asset purchase agreement to acquire Worcester manufacturing facility of Mustang Bio, Inc. for $11 million.	23-05-17	CI
Mustang Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Mustang Bio to Implement 15-for-1 Reverse Stock Split	23-04-03	MT
Mustang Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Mustang Bio, Inc.

Equities

MBIO

US62818Q2030

Highlights

Filters